Experiment 2. FSL and FRL animals received single injections of CBD (10 or 30 mg/Kg, ip), ketamine (10 mg/Kg, ip) or vehicle and were submitted to the forced swimming test (FST) 1h later. 
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Early life stress increases stress vulnerability through BDNF gene epigenetic changes in the rat hippocampus 
Abstract
Hypercortisolemia is suggested to associate with the onset of depressive symptoms in clinical patients [1] [2] . Monoamine oxidases (MAO), the enzymes maintaining the turnover and homeostasis of monoamine neurotransmitter, is up-regulated upon exposure to glucocorticoid in in vitro studies [3] [4] . However, the mechanistic involvement of MAO in monoamine deficiency, oxidative stress and neuroinflammation in rodent model of hypercortisolemia is not fully understood. Drug M30 comprises brain selective MAO inhibition and iron-chelating free radical scavenging moieties, and has been demonstrated protective in various neurodegernative disease models [5] [6] . This study aims to investigate the neuroprotective effect of M30 against depressive-like behavior induced by chronic corticosterone (CORT) treatment. Adult male Sprague-Dawley rats (220-250g) were given subcutaneous CORT injections with or without concurrent M30 application for 14 days. CORT-treated rats showed significant depressive-like behavior with remarkable increases in plasma corticosterone level. Chronic CORT treatment elicited the increases in MAO activities, serotonin turnover, oxidative stress, neuroinflammation and apoptosis in the hippocampus when compared with the control group. In addition, the cytokine-responsive serotonin and tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO-1) was significantly elevated in the CORT-treated group resulting in serotonin deficiency. Moreover, CORT-treatment impaired the neuroarchitecture of pyramidal CA1 and CA3 neurons. M30 application promisingly abrogated the adverse alterations in the hippocampus and protected the rat against depressive-like behavior provoked by CORT. Therefore, our results provide a strong support that M30 is neuroprotective against depressive-like behavior resulting induced by CORT by antagonizing overactivation of MAO-A that trigger oxidative stress, neuroinflammation, IDO-1 activation, serotonin deficiency and neurodegeneration. 
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Suppression of reward-induced dopamine release in the nucleus accumbens of the chronic mild stress model rats
Saki Minami, Hiroshi Satoyoshi, Soichiro Ide, Masabumi Minami Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University
Abstract One of the main symptoms of major depressive disorder is an inability to experience pleasure, anhedonia. Dopaminergic neurons projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) constitute the brain reward system. Various kinds of rewards and drugs of abuse elevate the dopamine (DA) release in the NAc, which is considered to be important to generate pleasant emotion. In the animal models of depression, sucrose preference is reported to be reduced, and this reduction is thought to be due to the suppression of VTA dopaminergic neurons. In this study, using a chronic mild stress (CMS) model which is one of the animal models of depression, we examined the influence of CMS on reward-induced DA release in the NAc and the effect of SSRI treatment on the alteration of DA release induced by CMS. Male Sprague-Dawley rats (4 week old at the start of CMS) were exposed to CMS for 4 weeks. Then, escitalopram (10 mg/kg/day) or vehicle was intraperitoneally administered for 3 weeks. Extracellular DA levels in the NAc were measured using an in vivo microdialysis technique, and reward (30% sucrose water)-induced DA release was examined. In the non-CMS groups, the reward elevated extracellular DA levels regardless of presence or absence of SSRI treatment. In the CMS group without SSRI treatment, the reward-induced DA release disappeared. Chronic treatment with escitalopram recovered the reward-induced DA release in the CMS group. These results suggest the possibility that the reward-induced DA release in the NAc is useful for an index to quantitatively evaluate the anhedonic condition and the effect of SSRI treatment.
